Fig. 4
Observed day 28 cerebrospinal fluid (CSF) amyloid-β 1–40 (Aβ1–40) percentage reduction from baseline in Caucasian patients with preclinical Alzheimer’s disease (AD) and mild cognitive impairment (MCI) due to AD (ALZ1005) vs. model-based simulations from pharmacokinetic/pharmacodynamic modeling. The observed data of CSF Aβ1–40 percentage vs. baseline, stratified by patient population (preclinical AD vs. MCI due to AD) from Study ALZ1005, are overlaid on the model-predicted median and 90% prediction interval (5th and 95th percentiles, gray-shaded area) from 500 simulations per dose level